Scarica l'app Stockscreener
7.84
3.69%
-0.30
Dopo l'orario di chiusura:
7.84
Precedente Chiudi:
$8.14
Aprire:
$8.22
Volume 24 ore:
533.80K
Relative Volume:
2.04
Capitalizzazione di mercato:
$134.11M
Reddito:
$10.73M
Utile/perdita netta:
$-455.74M
Rapporto P/E:
-2.0725
EPS:
-3.7829
Flusso di cassa netto:
$-502.70M
1 W Prestazione:
-5.43%
1M Prestazione:
-44.24%
6M Prestazione:
-41.67%
1 anno Prestazione:
-82.25%
Intervallo 1D:
$7.68
$8.4211
Intervallo di 1 settimana:
$7.68
$8.515
Portata 52W:
$7.68
$73.06
Atrium Therapeutics Inc Stock (RNA) Company Profile
Nome
Atrium Therapeutics Inc
Settore
Industria
Telefono
858-401-7900
Indirizzo
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNA
Atrium Therapeutics Inc
|
7.84 | 141.81M | 10.73M | -455.74M | -502.70M | -3.7829 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atrium Therapeutics Inc Stock (RNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Iniziato | Wells Fargo | Overweight |
| 2025-09-17 | Iniziato | Roth Capital | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Bernstein | Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-06-11 | Iniziato | Raymond James | Strong Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-09-24 | Iniziato | Goldman | Buy |
| 2024-08-28 | Iniziato | Barclays | Overweight |
| 2024-05-03 | Iniziato | BofA Securities | Buy |
| 2024-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Strong Buy |
| 2021-09-07 | Iniziato | Evercore ISI | Outperform |
| 2021-06-17 | Iniziato | Needham | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | Cowen | Outperform |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | SVB Leerink | Outperform |
| 2020-07-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Atrium Therapeutics Inc Borsa (RNA) Ultime notizie
Form 4 Atrium Therapeutics Inc For: 27 September By Investing.com - Investing.com Canada
Atrium Therapeutics stock advances its RNA pipeline toward Phase I/ II - AD HOC NEWS
RNA: Atrium Therapeutics Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Atrium Therapeutics CMO Steven George Hughes Reports Tax-Related Share Withholding on RSU Vesting - kalkinemedia.com
Form 4 Atrium Therapeutics Inc For: 22 September - Investing.com India
Form 4 Atrium Therapeutics Inc For: 22 September By Investing.com - Investing.com Australia
Atrium Therapeutics (RNA) CSO now holds 41K shares after RSU tax withholding - Stock Titan
21K Atrium Therapeutics (RNA) shares withheld for CMO's taxes - Stock Titan
Director at Atrium Therapeutics (RNA) has 22,812 shares withheld for taxes - Stock Titan
Tax withholding trims Atrium Therapeutics (RNA) director's stake - Stock Titan
2,375 Atrium Therapeutics (RNA) shares withheld for taxes - Stock Titan
Tax withholding trims 11,632 Atrium Therapeutics (RNA) shares, not a market sale - Stock Titan
Atrium Therapeutics (RNA) executive now holds 38,340 shares after tax move - Stock Titan
One new hire gets 13,500 options and 6,750 stock units from Atrium Therapeutics - Stock Titan
Atrium Therapeutics, Inc.Common Stock (Nasdaq:RNA) Price Chart - The Chronicle-Journal
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Riding the Wave of a 141% Potential Upside - DirectorsTalk Interviews
Atrium Therapeutics at Wells Fargo conference: heart-rna push gains pace - Investing.com Nigeria
Atrium Therapeutics, Inc. (RNA): Analyst Consensus Highlights 76% Potential Upside for Biotechnology Innovator - DirectorsTalk Interviews
Atrium Therapeutics, Inc. (RNA) Stock Price, News, Quote & History - Yahoo Finance
Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real - Yahoo Finance
Atrium Therapeutics to Participate in Upcoming Investor Conferences - Investing News Network
Atrium Therapeutics, Inc. (RNA) - DirectorsTalk Interviews
Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform? - Yahoo Finance
Atrium Therapeutics, Inc. Share Price Live Today – NASDAQ:RNA Stock Price, Chart, News, History - upstox.com
Atrium Therapeutics, Inc. (RNA) Stock Analysis: A Biotech Player with a Potential 89% Upside - DirectorsTalk Interviews
BRIEF-Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - Dailyhunt
A new Atrium hire gets options on 11,000 shares and 5,500 restricted units - Stock Titan
Atrium (RNA) Momentum: Records a 1.68% Decrease to $13.48; Technical View: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingBreakaway Gap - vinanet.vn
Atrium (RNA) Earnings Reading: Profit Per Share Clears Its Benchmark for the Current Session; Price Reaction: The Stock Gains 6.78% in Latest TradingProfitability Analysis - careplusvn.com
Atrium (RNA) Closing Snapshot: Closes 0.93% Lower at $12.84 in Latest Trading; Level Check: the Supplied Trading Band Runs From $12.20 to $13.48 in the Latest ReadingStop Loss Guidance - vinanet.vn
Atrium Therapeutics (RNA) Inches Higher: 0.93% Gain Reinforces Support ZoneDark Pool Sentiment - vinanet.vn
Atrium Therapeutics (RNA) Climbs 2.4% as Shares Hold Above Critical SupportCup and Handle - dars.gov.et
Atrium Therapeutics, Inc. (RNA) Stock Analysis: 94.70% Potential Upside Catches Investor Attention - DirectorsTalk Interviews
Atrium Therapeutics (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Investor SentimentDividend Earnings Report - vinanet.vn
Atrium Therapeutics (RNA) Jumps 4.14% to $12.84 as Buyers Defend Key SupportValue Area High - vinanet.vn
Atrium Therapeutics (RNA) Climbs 4.1% to $12.84 as Biotech Sentiment StrengthensLow Beta Factor - Vinanet
Atrium Therapeutics (RNA): RA Capital and affiliates report 0% beneficial ownership - Stock Titan
Aterian: Q2 Earnings Snapshot - AOL.com
Sessa Capital discloses 8.8% Atrium Therapeutics (RNA) ownership through managed funds - Stock Titan
T. Rowe Price Associates (RNA) discloses 8.6% Atrium Therapeutics ownership in 13G/A - Stock Titan
Atrium Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | RNA | US04965N1046 - marketscreener.com
Atrium Therapeutics Q2 Net Loss Widens to $21.6 Million on Higher Spending - Minichart
Atrium Therapeutics Earns $15M BMS Milestone Payment, Advances Gene Therapy Candidate - Minichart
FDA clears IND for Atrium Therapeutics' ATR 1072 trial - scanx.trade
Form 8K Atrium Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Heart drug developer Atrium Therapeutics' Q2 loss widens as expenses rise - TradingView
Atrium Therapeutics Q2 Results: Sales beat 50%, EPS miss widens - scanx.trade
Atrium Therapeutics, Inc. Q2 2026: Revenue $3M, EPS $(1.18) — 10-Q Summary - TradingView
Atrium Therapeutics (RNA) grows collaboration revenue to $22.6M while scaling R&D spend - Stock Titan
Atrium Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Atrium Therapeutics Reports Second Quarter 2026 Financial Results - KITV
Atrium Therapeutics Inc Azioni (RNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atrium Therapeutics Inc Azioni (RNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Boyce Sarah | President and CEO |
Jan 21 '26 |
Sale |
72.45 |
14,387 |
1,042,338 |
269,007 |
| Flanagan W. Michael | Chief Scientific Officer |
Jan 21 '26 |
Sale |
72.45 |
6,534 |
473,388 |
85,093 |
| MacLean Michael F | Chief Financial Officer |
Jan 21 '26 |
Sale |
72.45 |
4,542 |
329,068 |
59,290 |
| LEVIN ARTHUR A | Director |
Jan 21 '26 |
Sale |
72.45 |
1,758 |
127,367 |
16,562 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 21 '26 |
Sale |
72.45 |
2,929 |
212,206 |
113,938 |
| Boyce Sarah | President and CEO |
Jan 07 '26 |
Sale |
72.23 |
8,576 |
619,444 |
283,394 |
| Calderaro Charles III | Chief Technical Officer |
Jan 07 '26 |
Sale |
72.23 |
3,727 |
269,201 |
49,797 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 07 '26 |
Sale |
72.23 |
1,965 |
141,932 |
116,867 |
| Moriarty John B | Chief Legal Officer |
Jan 07 '26 |
Sale |
72.23 |
2,374 |
171,474 |
74,557 |
| MacLean Michael F | Chief Financial Officer |
Jan 07 '26 |
Sale |
72.23 |
1,974 |
142,582 |
63,832 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):